The presence of CD16a+ immune cells in the tumor associates with greater sensitivity to chemotherapy and longer progression-free survival (PFS) and overall survival in patients with recurrent HGSC (25), suggesting a role for CD16a+ cells in tumor control. Here, FCGR3A is linked to neoplasm.